Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.36 · Revenue $14.32M · 5 analysts
Est. EPS $-0.38 · Revenue $14.19M · 5 analysts
Est. EPS $-1.50 · Revenue $52.85M · 7 analysts
Est. EPS $-0.38 · Revenue $12.94M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $51.8M | -18.7% | +24.9% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-265.9M | -37.4% | +11.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +87.3% | -4.2% | -3.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -521.0% | -93.3% | +29.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -513.2% | -69.0% | +28.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-216.9M | -59.5% | +0.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -418.5% | -96.2% | +20.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 12.2% | -49.3% | +11.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 15.39x | +44.4% | -11.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $808.1M | +76.5% | -8.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.42 vs -1.45 | +2.3% | -0.35 vs -0.36 | +4.0% |
| Revenue Surprise | $51.8M vs $54.8M | -5.4% | $13.5M vs $14.3M | -5.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Notman Donald | officer: Chief Operating Officer | Common Stock | D | 1,099 | $10.24 |
| Aug 25, 2026 | Dugel Pravin | director, officer: See Remarks | Common Stock | A | 50,092 | — |
| Aug 25, 2026 | Dugel Pravin | director, officer: See Remarks | Common Stock | D | 50,092 | — |
| Aug 24, 2026 | Kaiser Peter | officer: Chief Development Officer | Common Stock | D | 3,035 | $10.77 |
| Aug 24, 2026 | Nayak Sanjay | officer: Chief Strategy Officer | Common Stock | D | 1,897 | $10.78 |
Operator: Good morning, and welcome to the Ocular Therapeutics First Quarter 2026 Earnings Conference Call. As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutics website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery, Jr. Please go ahead, Mr. Slattery. William Slattery: Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our quarterly report on Form 10-Q outlining our financial results and business updates for the first quarter of 2026. During today's call, Ocular's Executive Chairman, President and CEO, Dr. Pravin Dugel, will summarize recent business highlights before we move to our question-and-answer session. Joining Dr. Dugel for the Q&A portion of the call will be Donald Notman, Chief Operating Officer; Sanjay Nayak, Chief Strategy Officer; and Steve Meyers, Chief Commercial Officer. We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of our first quarter 2026 financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of a variety of risk factors, including risks and uncertainties identified in the Risk Factors section of our annual report on Form 10-K and our other SEC filings. With that, I'd like to hand the call over to Dr. Pravin Dugel to review our recent updates. Pravin? Pravin Dugel: Thank you, Bill, and thank you all for joining us this morning. 2026 is off to a tremendous start for Ocular Therapeutics. And I want to begin by stating this clearly. SOL-1 has fundamentally changed the conversation in wet AMD. In February, AXPAXLI became the first novel investigational therapy to demonstrate superiority to an approved anti-VEGF agent in a Phase III wet AMD trial. That has never been done before. The magnitude, consistency and statistical strength of the data with a p-value of 0.0006 for our primary endpoint are giving the retina community great confidence in the robustness of the result and the probability of a potential approval as we prepare to submit our NDA based on SOL-1 week 52 data, subject to ongoing formal discussions with the U.S. FDA. But beyond the statistics, what truly excites us is the clinical significance of the data. AXPAXLI delivered unmatched durability and sustained disease control with substantially fewer rescues. In 2/3 of the patients, just a single AXPAXLI injection maintained vision for an entire year. That is not incremental progress. That is true differentiation. Most importantly, we're not slowing down. Just last week, we announced the initiation of enrollment in SOL-X, our long-term extension trial in wet AMD designed to explore AXPAXLI's …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Pravin U. Dugel | Executive Chairman, President & Chief Executive Officer | USD 1,771,958 | — | 1964 | Active |
Donald Notman Jr. | Chief Operating Officer (Leave of Absence) | USD 969,180 | Male | — | Active |
Nadia K. Waheed | Chief Medical Officer | USD 935,795 | — | 1977 | Active |
Sanjay Nayak MBBS | Chief Strategy Officer | USD 845,653 | Male | 1970 | Active |
Steve Meyers | Chief Commercial Officer | USD 808,678 | Male | — | Active |
Peter K. Kaiser | Chief Development Officer | USD 698,866 | — | 1967 | Active |
Jeffrey S. Heier | Chief Scientific Officer | USD 676,550 | — | 1961 | Active |
Jason Robins | CFO & Principal Accounting Officer | — | Male | 1977 | Active |
William S. Slattery Jr. | Vice President of Investor Relations | — | Male | — | Active |
Peter K. Jarrett | Chief Technical Officer | — | — | 1957 | Active |
Todd Anderman | Chief Legal Officer & Corporate Secretary | — | Male | 1982 | Active |
William H. Ransone | Vice President of Global Sales & Marketing | — | Male | — | Active |
BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of the biopharmaceutical company's stock, valued at approximately $190,278,000. BlackRock Inc. owned 8.82% of Ocular Therapeutix as of its most recent filing with
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Ocular Therapeutix Inc. (NASDAQ:OCUL) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ:EYPT).
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Beth Rada, the Company's new SVP, Government Affairs and Public Policy. The awards were made as an inducement material to the recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
California State Teachers Retirement System increased its holdings in Ocular Therapeutix, Inc. (NASDAQ: OCUL) by 41.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 213,706 shares of the biopharmaceutical company's stock after acquiring an additional 63,005 shares during the quarter. California
